期刊论文Resistant Hypertension Effectively Treated With Novel Drug.复制

DOI:复制

文献链接:复制

其他信息:

N Persaud
Medical Bag, 2022
go.gale.com
Aprocitentan, a dual endothelin receptor A and B antagonist, shows modest efficacy in treating resistant hypertension, but is associated with increased risks for edema and fluid retention, according to new study findings.In part 1 of the PRECISION study, investigators randomly assigned 730 patients to receive aprocitentan 12.5 mg, aprocitentan 25 mg, or placebo for 4 weeks. In part 2, all patients received aprocitentan 25 mg for 32 weeks. In part 3, the withdrawal phase, investigators randomly assigned patients to receive aprocitentan …